LDL Electronegativity- a novel determinant of mortality risk in ASCVD
Simon Kraler et al. and colleagues from the Center for Molecular Cardiology, University of Zurich, have highlighted that Reduced low-density lipoprotein (LDL) electronegativity is associated independently with mortality risk at 30 days and one year after the acute event. LDL electronegativity supersedes several risk factors for predicting 1-year death, including LDL cholesterol. When added to...
Simon Kraler et al. and colleagues from the Center for Molecular Cardiology, University of Zurich, have highlighted that Reduced low-density lipoprotein (LDL) electronegativity is associated independently with mortality risk at 30 days and one year after the acute event. LDL electronegativity supersedes several risk factors for predicting 1-year death, including LDL cholesterol. When added to the GRACE risk score, it enhances the discriminatory performance of the score. Overall, this study has proved that LDL quality determines outcomes in ASCVD patients.
LDL particles of different electronegativity have a distinct lipidome, with potential implications for their athero-/thrombogenicity. It is a determining factor for mortality risk in patients with established atherosclerotic cardiovascular disease.
Low-density lipoprotein (LDL)-cholesterol (LDL-C) promotes atherosclerotic cardiovascular disease (ASCVD), with changes in LDL electronegativity modulating its pro-atherogenic/pro-thrombotic effects.
There needs to be more data on Whether such alterations are associated with adverse outcomes in patients with a history of acute coronary syndromes ACS. These patients are at high cardiovascular risk.
The study design included 2619 patients who had a history of ACS. They assessed LDL electronegativity and lipidome.
The essential points of research design are:
- There was an association between LDL electronegativity changes and all-cause mortality at 30 days with aHR and one year with a notable association with cardiovascular mortality.
- LDL electronegativity superseded traditional risk factors.
- LDL electronegativity improves GRACE score performance.
- Enriched lipid species (L1 vs L5) were independently linked to the mortality risk.
They said altered LDL quality is a novel determinant of adverse outcomes in ACS patients.
We demonstrate for the first time that attenuated LDL electronegativity, as assessed by the L1-L5 ratio, unfavourably associates with all-cause and cardiovascular mortality after the index ACS, over and above the updated GRACE risk score, they said.
Electronegative properties of LDL particles are tightly linked to alterations in their lipidome and represent a novel determinant of mortality risk in patients with ACS.
https://www.atherosclerosis-journal.com/article/S0021-9150(23)00207-1/fulltext
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd